Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib plus fulvestrant after prior CDK4/6 inhibitor progression in HR-positive/HER2-negative advanced breast cancer
2019-000221-45Phase 2Active
- Sponsor
- Consorzio Oncotech
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of palbociclib and fulvestrant in breast cancer, sponsored by Consorzio Oncotech. Primary endpoint: Clinical benefit rate. Started Jun 2021; status: active.
02
Drugs
palbociclibfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2019-000221-45.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000221-45.